Bladder cancer

Current Opinion in Oncology

Volumn 23, Issue 3, 2011, Pages 275-282

  Morgan, Todd M ^a   Keegan, Kirk A ^a   Clark, Peter E ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

bladder cancer; diagnosis; review; treatment

Indexed keywords

BCG VACCINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; LAPATINIB; METHOTREXATE; MITOMYCIN C; PAZOPANIB; TAMOXIFEN; VINBLASTINE; VINFLUNINE; VORINOSTAT;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER STAGING; CYSTECTOMY; CYSTOSCOPY; DISEASE MARKER; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; METASTASIS; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ROBOTICS; SMOKING; TRANSITIONAL CELL CARCINOMA;

CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; URINARY BLADDER NEOPLASMS;

EID: 79955042173     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283446a11     Document Type: Review

References (94)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Grimbergen MC, van Swol CF, Jonges TG, et al. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 2003; 44:51-56. (Pubitemid 36741375)
3. de Bekker-Grob EW, van der Aa MN, Zwarthoff EC, et al. Nonmuscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative? BJU Int 2009; 104:41-47.
4. Shirodkar SP, Lokeshwar VB. Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol 2009; 19:488-493.
5. Patil VV, Wang ZJ, Sollitto RA, et al. 18F-FDG PET/CT of transitional cell carcinoma. AJR Am J Roentgenol 2009; 193:W497-W504.
6. TotaroA, Pinto F, Brescia A, et al. Imaging in bladder cancer: present role and future perspectives. Urol Int 2010; 85:373-380.
7. Apolo AB, Riches J, Schoder H, et al. Clinical value of fluorine-18 2-fluoro-2- deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 2010; 28:3973-3978.
8. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178:2314-2330. (Pubitemid 350080987)
9. Madeb R, Golijanin D, Noyes K, et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer 2009; 115:2660-2670.
10. Miyake M, Sugano K, Sugino H, et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in nonmuscle invasive bladder cancer. Cancer Sci 2010; 101:250-258.
11. Muramaki M, Miyake H, Terakawa T, et al. Expression profile of E-cadherin and N-cadherin in nonmuscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol 2010. [Epub ahead of print]
12. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calm-ette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163:1124-1129.
13. Mohanty NK, Nayak RL, Vasudeva P, et al. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder: our experience. Urol Oncol 2008; 26:616-619.
14. PerdonaS, Di Lorenzo G, Cantiello F, et al. Isgemcitabinean option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs 2010; 21:101-106.
15. Di Lorenzo G, Perdona S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in nonmuscle- invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010; 116:1893-1900.
16. Barlow L, McKiernan J, Sawczuk I, et al. A single-institution experience with induction and maintenance intravesical docetaxel in the management of nonmuscle-invasive bladder cancer refractory to bacille Calmette-Guerin therapy. BJU Int 2009; 104:1098-1102.
17. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000; 163:761-767. (Pubitemid 30091611)
18. Di Stasi SM, Riedl C. Updates in intravesical electromotive drug administration of mitomycin-Cfor nonmuscle invasive bladder cancer. World J Urol 2009; 27:325-330.
19. Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for nonmuscle-invasive bladder cancer (NMIBC). BJU Int 2010. [Epub ahead of print]
20. Dutta SC, Smith JA Jr, Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001; 166:490-493. (Pubitemid 32652229)
21. Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010; 57:60-70.
22. Weizer AZ, Wasco MJ, Wang R, et al. Multiple adverse histological features increase the odds of under staging T1 bladder cancer. J Urol 2009; 182:59-65.
23. Cho KS, Seo HK, Joung JY, et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 2009; 182:2625-2630.
24. Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk nonmuscle invasive bladder cancer (T1 G3). World J Urol 2009; 27:347-351.
25. Stein J, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666-675. (Pubitemid 32120143)
26. Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24:3967-3972. (Pubitemid 46630745)
27. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006; 176:1354-1361.
28. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006; 12:6663-6676. (Pubitemid 44876834)
29. Zaak D, Burger M, Otto W, et al. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int 2010; 106:342-348.
30. Bassi PF, Bongiovanni PL, Racioppi M, et al. Postoperative nomogram for invasive bladder cancer: does it really work? A multicenter cohort study. Urol Oncol 2009. [Epub ahead of print]
31. Bolenz C, Herrmann E, Bastian PJ, et al. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int 2010; 106:493-499.
32. Stimson CJ, Cookson MS, Barocas DA, et al. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol 2010; 183:1732-1737.
33. Tilki D, Svatek RS, Karakiewicz PI, et al. pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. J Urol 2010; 184:470-474.
34. LawrentschukN, Colombo R, Hakenberg OW, et al. Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol 2010; 57:983-1001.
35. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55:164-176.
36. Clavien PA, Barkun J, deOliveiraML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250:187-196.
37. Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol 2010; 184:990-994.
38. Gore JL, Yu H-Y, Setodji C, et al. Urinary diversion and morbidity after radical cystectomy for bladder cancer. Cancer 2010; 116:331-339.
39. Clark PE, Stein JP, Groshen SG, et al. Radical cystectomy in the elderly: comparison of survival between younger and older patients. Cancer 2005; 103:546-552.
40. MadersbacherS, Bauer W, Willinger M, et al. Radical cystectomy for bladder cancer in the 70+ population: a nation-wide registry analysis of 845 patients. Urol Int 2010; 85:287-290.
41. Stroumbakis N, Herr HW, Cookson MS, et al. Radical cystectomy in the octogenarian. J Urol 1997; 158:2113-2117. (Pubitemid 27481339)
42. Tilki D,ZaakD, Trottmann M, et al. Radical cystectomy in the elderly patient: a contemporary comparison of perioperative complications in a single institution series. World J Urol 2010; 28:445-450.
43. Isbarn H, Jeldres C, Zini L, et al. A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol 2009; 182:70-77.
44. Chamie K, Hu B, Devere White RW, et al. Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? BJU Int 2008; 102:284-290. (Pubitemid 352019198)
45. Lughezzani G, Sun M, Shariat SF, et al. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer 2011; 117:103-109.
46. Smith A, Kurpad R, Lal A, et al. Cost analysis of robotic versus open radical cystectomy for bladder cancer. J Urol 2010; 183:505-509.
47. Hellenthal NJ, Hussain A, Andrews PE, et al. Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol 2010; 184:87-91.
48. Pruthi RS, Nielsen ME, Nix J, et al. Robotic radical cystectomy for bladder cancer: surgical and pathological outcomes in 100 consecutive cases. J Urol 2010; 183:510-514.
49. Ng C, Kauffman E, Lee M, et al. A comparison of postoperative complications in open versus robotic cystectomy. Eur Urol 2010; 57:274-282.
50. Murphy DG, Challacombe BJ, Elhage O, et al. Robotic-assisted laparoscopic radical cystectomy with extracorporeal urinary diversion: initial experience. Eur Urol 2008; 54:570-580.
51. Pruthi RS, Smith A, Wallen EM. Evaluating the learning curve for robot-assisted laparoscopic radical cystectomy. J Endourol 2008; 22:2469-2474.
52. Hellenthal NJ, Hussain A, Andrews PE, et al. Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int 2010. [Epub ahead of print]
53. Nix J, Smith A, Kurpad R, et al. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol 2010; 57:196-201.
54. Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003; 169:943-945. (Pubitemid 36188130)
55. Wright JL, Lin DW, Porter MP. The association between extent of lympha-denectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 2008; 112:2401-2408.
56. Herr HW, Bochner BH, Dalbagni G, et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002; 167:1295-1298. (Pubitemid 34132073)
57. Fang AC, Ahmad AE, Whitson JM, et al. Effect of a minimum lymph node policy in radical cystectomy and pelvic lymphadenectomy on lymph node yields, lymph node positivity rates, lymph node density, and survivorship in patients with bladder cancer. Cancer 2010; 116:1901-1908.
58. Dangle PP, Gong MC, Bahnson RR, et al. How do commonly performed lymphadenectomy templates influence bladder cancer nodal stage? J Urol 2010; 183:499-503.
59. Jensen JB, Ulhøi BP, Jensen KM-E. Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery. BJU Int 2010; 106:199-205.
60. Rabbani F, Lee C, Chang SS, et al. Accuracy of the extent of bladder cancer nodal metastases found at pelvic lymphadenectomy at the time of cystect-omy: relation to primary tumor stage. Urol Int 2010; 84:14-22.
61. Seiler R, von Gunten M, Thalmann GN, et al. Pelvic lymph nodes: distribution and nodal tumour burden of urothelial bladder cancer. J Clin Path 2010; 63:504-507.
62. Jensen JB, Ulhøi BP, Jensen KM-E. Size and volume of metastatic and nonmetastatic lymph nodes in pelvis and lower abdomen in patients with carcinoma of the bladder undergoing radical cystectomy. Scand J Urol Nephrol 2010; 44:291-297.
63. Kassouf W, Agarwal PK, Herr HW, et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cy-stectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 2008; 26:121-126.
64. Stephenson AJ, Gong MC, Campbell SC, et al. Aggregate lymph node metastasis diameter and survival after radical cystectomy for invasive bladder cancer. Urology 2010; 75:382-386.
65. Calabrò F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2009; 55:348-358.
66. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859-866. (Pubitemid 37025405)
67. Collaboration ABCAM-a. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48:202-205; discussion 205-206.
68. Group EG-UC. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354:533-540.
69. Cuppone F, Bria E, Carlini P, et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer 2008; 113:238-246.
70. Miles BJW, Fairey AS, Eliasziw M, et al. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J 2010; 4:263-267.
71. Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011; 117:276-282.
72. Canter D, Viterbo R, Kutikov A, et al. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 2011; 77:160-165.
73. Pruthi RS, Nielsen M, Heathcote S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int 2010; 106:349-356.
74. Tilki D, Svatek RS, Novara G, et al. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol 2010; 184:888-894.
75. Collaboration ABCAM-a. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 48:189-199.
76. Svatek RS, Shariat SF, Lasky RE, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010; 16:4461-4467.
77. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10:1066-1073.
78. Dash A, Pettus JA, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008; 113:2471-2477.
79. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602-4608. (Pubitemid 46224062)
80. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42:50-54. (Pubitemid 41814532)
81. Small EJ, Lew D, Redman BG, et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 2000; 18:2537-2544. (Pubitemid 30432519)
82. Calabrò F, Lorusso V, Rosati G, et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 2009; 115:2652-2659.
83. Dumez H, Martens M, Selleslach J, et al. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothe-lium: results of a phase II and pharmacologic study. Anticancer Drugs 2007; 18:211-218. (Pubitemid 44967431)
84. Carles J, Esteban E, Climent M, et al. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol 2007; 18:1359-1362. (Pubitemid 47305010)
85. Dreicer R, Li H, Cooney MM, et al. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer 2008; 112:2671-2675. (Pubitemid 351969210)
86. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115:4090-4095.
87. Wü lfing C, Machiels J-PH, Richel DJ, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115: 2881-2890.
88. Hahn NM, Statdler WM, Zon RT, et al. A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial cell carcinoma (UC): Hoosier Oncology Group GU-0475 [abstract]. In: Program and Abstracts of the 2009 ASCO Annual Meeting; 4-8 June 2009; Chicago, Illinois. Proc Am Soc Clin Oncol 2009; 27:5018.
89. Sherif A, Hasan MN, Marits P, et al. Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept. Eur Urol 2010; 58:105-111.
90. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27:4454-4461.
91. Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28:1850-1855.
92. Sonpavde G, Sternberg CN, Rosenberg JE, et al. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010; 11:861-870.
93. Cooperberg MR, Porter MP, Konety BR. Candidate quality of care indicators for localized bladder cancer. Urol Oncol 2009; 27:435-442.
94. Chamie K, Saigal C, Hanley J, et al. Quality of care for patients with high-grade nonmuslce invasive bladder cancer. J Urol 2010; 183e:568-569.